PIMAVANSERIN TARTRATE - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for pimavanserin tartrate and what is the scope of freedom to operate?
Pimavanserin tartrate
is the generic ingredient in two branded drugs marketed by Acadia Pharms Inc, MSN, and Zydus, and is included in five NDAs. There are fourteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.Pimavanserin tartrate has eighty-eight patent family members in twenty-two countries.
There are two drug master file entries for pimavanserin tartrate. One supplier is listed for this compound.
Summary for PIMAVANSERIN TARTRATE
International Patents: | 88 |
US Patents: | 14 |
Tradenames: | 2 |
Applicants: | 3 |
NDAs: | 5 |
Drug Master File Entries: | 2 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 32 |
Clinical Trials: | 3 |
Patent Applications: | 118 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for PIMAVANSERIN TARTRATE |
What excipients (inactive ingredients) are in PIMAVANSERIN TARTRATE? | PIMAVANSERIN TARTRATE excipients list |
DailyMed Link: | PIMAVANSERIN TARTRATE at DailyMed |
Recent Clinical Trials for PIMAVANSERIN TARTRATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
ACADIA Pharmaceuticals Inc. | Phase 2 |
ACADIA Pharmaceuticals Inc. | Phase 3 |
ACADIA Pharmaceuticals Inc. |
Pharmacology for PIMAVANSERIN TARTRATE
Drug Class | Atypical Antipsychotic |
Paragraph IV (Patent) Challenges for PIMAVANSERIN TARTRATE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
NUPLAZID | Tablets | pimavanserin tartrate | 10 mg | 207318 | 1 | 2020-04-29 |
NUPLAZID | Capsules | pimavanserin tartrate | 34 mg | 210793 | 5 | 2020-04-29 |
US Patents and Regulatory Information for PIMAVANSERIN TARTRATE
Expired US Patents for PIMAVANSERIN TARTRATE
International Patents for PIMAVANSERIN TARTRATE
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
South Korea | 101095939 | ⤷ Try a Trial | |
Poland | 1794126 | ⤷ Try a Trial | |
South Korea | 101260036 | ⤷ Try a Trial | |
Hong Kong | 1126776 | SELECTIVE SEROTONIN 2A/2C RECEPTOR INVERSE AGONISTS AS THERAPEUTICS FOR NEURODEGENERATIVE DISEASES | ⤷ Try a Trial |
New Zealand | 553702 | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms | ⤷ Try a Trial |
Mexico | 2007003433 | SINTESIS DE N-FLUOROBENCIL) -N- (1-METILPIPERIDIN-4-IL) -N'- (4- (2-METILPROPILOXI) FENILMETIL) CARBAMIDA Y SU SAL DE TARTRATO Y FORMAS CRISTALINAS. (SYNTHESIS OF N-(4-FLUOROBENZYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(4- (2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND CRYSTALLINE FORMS.) | ⤷ Try a Trial |
Japan | 2010174026 | SELECTIVE SEROTONIN 2A/2C RECEPTOR INVERSE AGONIST AS THERAPEUTIC FOR NEURODEGENERATIVE DISEASE | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.